Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockMolecular Profile
Molecular Profile
Type
Synthetic peptide (hexapeptide)
Molecular formula
C45H55N9O6
Molecular weight
817.97 g/mol
CAS number
158861-67-7
Amino acids
6
Sequence
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Modification
N-terminal D-Ala; D-2-naphthylalanine; D-Phe; C-terminal amide.
Mechanism & Target Class
Mechanism & Target Class
A synthetic, C-terminally amidated hexapeptide built from non-natural D-amino acids and a 2-naphthylalanine residue at position 2 — structural features studied for their contribution to enzymatic stability and receptor-binding interaction. It binds within the orthosteric pocket of a class A G protein-coupled receptor; that pocket has been resolved in cryo-EM structures of the receptor bound to its endogenous peptide ligand together with related synthetic peptide and non-peptide ligands, defining the shared binding-pocket geometry relevant to this peptide class. Pharmacokinetic characterization describes a small, unmodified peptide subject to enzymatic and aqueous degradation with a short reported plasma half-life.
Storage & Handling
Storage & Handling
Lyophilized
20°C
typically stable 24-36 months desiccated.
Avoid freeze-thaw; aliquot; protect from light and moisture.
References
References
Reviews
- 1
Ishida J, et al. (2020). JCSM Rapid Communications
- 2
Berlanga-Acosta J, Abreu-Cruz A, García-del Barco Herrera D, et al. (2017). Clinical Medicine Insights: Cardiology
Reviews
- 3
Adis Editorial. (2004). Drugs in R&D
- 4
Bowers CY. (1998). Comprehensive Physiology
Clinical
- 5
Kimura T, et al. (2010). Endocrine Journal
- 6
Kageyama K, et al. (2008). Endocrine Journal
- 7
Laferrère B, Abraham C, Russell CD, Bowers CY. (2005). J Clin Endocrinol Metab
- 8
Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, et al. (2002). Clinical Endocrinology (Oxford)
- 9
Gondo RG, et al. (2001). J Clin Endocrinol Metab
- 10
Mericq V, Cassorla F, Salazar T, Avila A, et al. (1998). J Clin Endocrinol Metab
- 11
Arvat E, Di Vito L, Maccagno B, Broglio F, et al. (1997). Peptides
- 12
Bowers CY, Reynolds GA, Durham D, Barrera CM, et al. (1990). J Clin Endocrinol Metab
Primary research
- 13
Králík F, Kvíčalová A, Salaďáková A, Kuchař M, Setnička V. (2026). Chirality
- 14
Zeng P, Li S, Zheng Y, Liu FY, Wang J, Zhang D, Wei J. (2014). Peptides
- 15
Wang Y, et al. (2021). Nature Communications
- 16
Structural-biology study group. (2021). Nature Communications
- 17
Nagaya N, et al. (2010). PubMed
- 18
Furuta S, Hori T, Ohyama T. (2006). Naunyn-Schmiedeberg's Archives of Pharmacology
- 19
Hirotani C, Oki Y, Ukai K, Okuno T, et al. (2005). Naunyn-Schmiedeberg's Archives of Pharmacology
- 20
Yan X, et al. (2004). European Journal of Endocrinology
- 21
Doi N, Hirotani C, Ukai K, Shimada O, et al. (2004). Arzneimittelforschung
- 22
Furuta S, Shimada O, Doi N, Ukai K, et al. (2004). Arzneimittelforschung
- 23
Cardioprotection study group. (2000). PubMed
- 24
Shepherd BS, et al. (2000). Journal of Endocrinology
- 25
Pharmacology study group. (1996). PubMed
Primary Database
Primary Database
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
